brigham buhler bpc 157 Our founder, Buhler, was a guest on the latest episode of The @JoeRogan Experience! 🙌 They discussed the broken healthcare system, the future of peptides, and some exciting new offerings coming Brigham Buhler on Peptide Quality

A 2019 randomized controlled trial of lipotropic injections (methionine, inositol, choline, B12) versus saline placebo in 120 participants on ad libitum diets found 0.8 kg (1.76 pounds) difference at 12 weeks, not statistically significant (p=0.18) (Karbalay-Doust et al., Journal of Research in Medical Sciences , 2019)

This form of supplementation provides a rapid and efficient absorption rate, as it bypasses the digestive system

For patients who have difficulty absorbing B12 through the digestive tractsuch as those with pernicious anemia, gastrointestinal disorders (like Crohns disease or celiac disease), a history of gastric bypass surgery, or those with severe B12 deficiencyour providers often recommend intramuscular B12 injections

The BPC-157 + TB-500 two-peptide blend pairs the compound with TB-500 at a 1:1 mass ratio for the angiogenic-plus-cytoskeletal pathway combination